File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Preventing renal failure in patients with severe lupus nephritis

TitlePreventing renal failure in patients with severe lupus nephritis
Authors
Issue Date2005
Citation
Kidney International, Supplement, 2005, v. 67 n. 94, p. S-116-S-119 How to Cite?
AbstractBackground and Methods. Advances in immunosuppressive treatment regimens, with increased efficacy, while minimizing the treatment-related toxicities, and better prevention and treatment of complications, have resulted in improved patient and renal survival in subjects with severe proliferative lupus nephritis over the past few decades. This review discusses the issues that are pertinent to the preservation of renal function in these patients. Results and Conclusion. Treatment of severe proliferative lupus nephritis can be divided into an initial phase of induction followed by a prolonged maintenance phase, both of which impact upon the long-term renal and patient survival. The immunosuppressive potency of the treatment required for disease control varies according to the disease activity during the different phases. Despite variations in the choice, duration, and route of administration of antiproliferative agents, data to date suggest that immunosuppresive treatments combining cyclophosphamide or mycophenolate mofetil with corticosteroid appear to have similar efficacy in terms of inducing immunologic remission. In this regard, the immunologic efficacy of treatment is prerequisite to the prevention of irreversible loss of nephrons, but long-term renal outcome is also dependent on factors other than treatment efficacy, such as preexisting renal parenchymal damage and blood pressure control. Prompt diagnosis, early effective therapy, and reducing the risk of relapses are the disease specific measures that are essential to long-term renal preservation and the prevention of renal failure in subjects with severe proliferative lupus nephritis. © 2005 by the International Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/163557
ISSN
2014 SCImago Journal Rankings: 0.578
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:37:23Z-
dc.date.available2012-09-05T05:37:23Z-
dc.date.issued2005en_US
dc.identifier.citationKidney International, Supplement, 2005, v. 67 n. 94, p. S-116-S-119en_US
dc.identifier.issn0098-6577en_US
dc.identifier.urihttp://hdl.handle.net/10722/163557-
dc.description.abstractBackground and Methods. Advances in immunosuppressive treatment regimens, with increased efficacy, while minimizing the treatment-related toxicities, and better prevention and treatment of complications, have resulted in improved patient and renal survival in subjects with severe proliferative lupus nephritis over the past few decades. This review discusses the issues that are pertinent to the preservation of renal function in these patients. Results and Conclusion. Treatment of severe proliferative lupus nephritis can be divided into an initial phase of induction followed by a prolonged maintenance phase, both of which impact upon the long-term renal and patient survival. The immunosuppressive potency of the treatment required for disease control varies according to the disease activity during the different phases. Despite variations in the choice, duration, and route of administration of antiproliferative agents, data to date suggest that immunosuppresive treatments combining cyclophosphamide or mycophenolate mofetil with corticosteroid appear to have similar efficacy in terms of inducing immunologic remission. In this regard, the immunologic efficacy of treatment is prerequisite to the prevention of irreversible loss of nephrons, but long-term renal outcome is also dependent on factors other than treatment efficacy, such as preexisting renal parenchymal damage and blood pressure control. Prompt diagnosis, early effective therapy, and reducing the risk of relapses are the disease specific measures that are essential to long-term renal preservation and the prevention of renal failure in subjects with severe proliferative lupus nephritis. © 2005 by the International Society of Nephrology.en_US
dc.languageengen_US
dc.relation.ispartofKidney International, Supplementen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents - Therapeutic Useen_US
dc.subject.meshKidney Failure, Chronic - Prevention & Controlen_US
dc.subject.meshLupus Nephritis - Drug Therapyen_US
dc.titlePreventing renal failure in patients with severe lupus nephritisen_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid15752227-
dc.identifier.scopuseid_2-s2.0-15944403449en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-15944403449&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume67en_US
dc.identifier.issue94en_US
dc.identifier.spageSen_US
dc.identifier.epage116en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats